Blood Detection of EGFR Mutation For Iressa Treatment

Trial Profile

Blood Detection of EGFR Mutation For Iressa Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BENEFIT
  • Most Recent Events

    • 18 Oct 2017 Results (n=152; data cut off: January 31, 2017) assessing efficacy presented at the 18th World Conference on Lung Cancer.
    • 22 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 22 Feb 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top